Two sponsors, two assets, two pauses. The variable they have in common sits in the manufacturing suite, not in the construct
Two sponsors paused their autoimmune CAR-T trials at the same time.
Different assets. Both built on a rapid manufacturing platform.
Novartis has temporarily halted development of its autologous CD19 CAR-T across several autoimmune indications, after three deaths from complications of serious IEC-HS. Bristol Myers Squibb has separately paused enrolment in the autoimmune trials of its own autologous CD19 CAR-T. Analysts at William Blair raised a question that reaches past both assets.
What Novartis paused
The asset is rapcabtagene autoleucel, known as rap-cel or YTB323. It is an autologous CD19-targeted CAR-T, designed to reprogram a patient's own T cells to clear CD19-expressing B cells. Novartis confirmed to Fierce Biotech on Monday that it has temporarily halted development in several autoimmune indications in immunology and neuroscience.
The trigger was three deaths. Each came from complications caused by serious immune effector cell-associated hemophagocytic syndrome, or IEC-HS.
Three deaths from IEC-HS complications. The oncology programme in the same asset is not affected.
Screening, randomisation and treatment administration are all on hold across the affected studies. Patients already treated in those trials continue to be monitored per protocol.
Novartis framed the halt as a review step, not a conclusion. "The temporary halt will allow for a more comprehensive review of the evolving clinical and safety data across the program, following three serious immune effector cell-associated hemophagocytic syndrome (IEC-HS) events," the company said in an email to Fierce.
Fierce updated its story later the same evening to confirm that those three serious IEC-HS cases were deaths.
The Novartis studies on hold
- Phase 2: systemic lupus erythematosus and lupus nephritis (CYTB323J12201), systemic sclerosis (CYTB323K12201), ANCA-associated vasculitis (CYTB323I12201), idiopathic inflammatory myopathies (CYTB323L12201).
- Phase 1/2: rheumatoid arthritis and Sjogren's disease, generalized myasthenia gravis, relapsing multiple sclerosis, non-active progressive multiple sclerosis (CYTB323M12101B, CYTB323O12101, CYTB323N12101, CYTB323R12101).
- On hold: screening, randomisation and treatment administration.
- Not affected: the oncology programme with the same asset, covering chronic lymphocytic leukemia and small lymphocytic lymphoma, diffuse large B-cell lymphoma, adult acute lymphoblastic leukemia and high-risk large B-cell lymphoma.
What IEC-HS is, and why the mechanism matters here
IEC-HS is a severe systemic inflammatory side effect associated with immunotherapies such as CAR-T. It is not a new or exotic entity in this field.
What matters for this story is the described trigger. The reaction may be set off when engineered T cells expand and activate rapidly inside the patient's body.
Hold that word: expansion. It comes back.
What Bristol Myers Squibb paused
In a Monday note to clients, William Blair analysts flagged that BMS had paused enrolment in its autoimmune trials of zola-cel, or BMS-986353. Zola-cel is also an autologous CD19-targeted CAR-T. William Blair reported that in a follow-up the company disclosed the pause was due to "transient and reversible inflammatory events."
BMS itself described the step as precautionary. "Out of an abundance of caution, we implemented a voluntary pause to review clinical data across our zola-cel program," a spokesperson told Fierce.
Zola-cel acts through the same CD19 mechanism as Breyanzi, the FDA-approved BMS treatment for relapsed and refractory blood cancers. Neither pause is described in the source as a regulator-imposed action. Both read as sponsor decisions.
The variable both programmes have in common
Rap-cel is manufactured on Novartis' T-Charge platform. Novartis describes T-Charge as a rapid manufacturing platform that allows for fewer exhausted T cells and removes the need for extended culture time outside the body.
Zola-cel was developed on BMS' NEXT T platform. BMS describes NEXT T as designed to encourage the growth of more uniform and potent T cells, which may prompt a deeper and more durable response.
Different sponsors, different assets, one shared feature: a rapid manufacturing platform.
That is the observation William Blair acted on. Because both assets were developed using rapid manufacturing platforms, the analysts suggested "that rapid manufacturing could be driving increased cell expansion and the reported toxicities."
Read that sentence at the strength it was written. It is a suggestion in an analyst note, tied to a plausible mechanism, and nothing more. No sponsor has said it, no regulator has said it, and no dataset published so far establishes cause.
If you have run a process-development call like this one, CMC experts get matched to paid consulting work through GTC's Expert Network: join free.
What this means for drug developers
If the analyst read holds, the exposure does not sit with two assets. It sits with a process choice that many programmes have made.
Rapid manufacturing was adopted for reasons that have little to do with the construct. Shorter culture time cuts cost and shortens vein-to-vein time, and both are real constraints in autologous cell therapy. Novartis' own description of T-Charge names the product-quality argument alongside them: fewer exhausted T cells.
Now put that next to the IEC-HS trigger described above. A less exhausted, more potent product is meant to expand well in the patient. The open question is whether, in a non-oncology setting, it can expand too well.
That is a CMC question wearing clinical clothes. It lands on process development, not on the CAR construct.
Two things are worth having in writing if you are running an autologous CAR-T on a compressed process today. First, a documented rationale linking your process parameters to expansion kinetics in the patient. Second, a safety monitoring plan that names IEC-HS specifically rather than folding it into a general inflammatory bucket.
None of that is a reason to walk away from rapid manufacturing. It is a reason to be able to answer the question the first time somebody asks it.
What this means for investors
Look at the indication list Novartis paused: lupus, systemic sclerosis, vasculitis, myositis, rheumatoid arthritis, Sjogren's disease, myasthenia gravis and multiple sclerosis. That list is the expansion thesis for CAR-T. It moves the modality from refractory blood cancer into chronic autoimmune disease.
The source gives no patient numbers, so treat the size of that opportunity as an assumption rather than a figure. What is not an assumption is direction. Autoimmune indications are where the addressable population gets much larger, and that is exactly the segment now on hold at two companies.
A platform-level safety question does not end that thesis. It changes its timing, and timing is most of what a single-asset valuation is made of.
One detail is worth holding on to. Novartis said explicitly that its oncology programme with the same asset is not affected.
That tells you where the sponsor drew the line today. It does not tell you the review will end there. Reading it as an all-clear for the asset is an inference Novartis has not made.
The wider impact on the field
The CD19 CAR-T space in autoimmune disease is crowded, and the same report names three programmes still moving. Cabaletta Bio plans to submit resecabtagene autoleucel, or rese-cel, for approval in the second half of next year in myositis.
Miltenyi Biomedicine reported in April that its asset zorpocabtagene-autoleucel, or zorpo-cel, drove three autoimmune diseases into remission in one patient. Fate Therapeutics reported improvements in patients with treatment-resistant systemic sclerosis dosed with FT819.
One of those three is not an autologous product. FT819 is described as off-the-shelf, which puts it on a different manufacturing footing entirely.
If a rapid autologous process turns out to matter here, that difference stops being a footnote about supply logistics. It becomes a safety argument. That is conditional on a hypothesis nobody has tested yet, and it should be read that way.
GTC's take
Two pauses at two companies is a coincidence until somebody names the shared variable. William Blair named one. Whether it survives contact with the data is genuinely open.
What is not open is where the question lands. It lands on process development. Both companies describe the same trade on their own platform pages: speed and potency, bought with a shorter process.
Much of our work with drug developers comes down to separating what a dataset shows from what it is being asked to carry. Here the dataset shows three deaths in one programme and an enrolment pause in another. What it is being asked to carry is a verdict on an entire manufacturing paradigm.
The useful work this week is not a position on that verdict. It is a written link between your process parameters, your expansion data and your safety monitoring plan.
Assembled before anyone asks, that document is a day of work. Assembled after a pause, it is a quarter.
Frequently asked questions
What did Novartis pause, and why?
Novartis temporarily halted development of rapcabtagene autoleucel (rap-cel; YTB323), an autologous CD19-targeted CAR-T, across several autoimmune indications in immunology and neuroscience. The trigger was three deaths from complications caused by serious immune effector cell-associated hemophagocytic syndrome (IEC-HS). Screening, randomisation and treatment administration are on hold across the affected studies, and patients already treated continue to be monitored per protocol. Novartis said the halt allows a more comprehensive review of the evolving clinical and safety data across the programme.
Which trials are affected, and is the oncology programme included?
Novartis confirmed Phase 2 studies in systemic lupus erythematosus and lupus nephritis (CYTB323J12201), systemic sclerosis (CYTB323K12201), ANCA-associated vasculitis (CYTB323I12201) and idiopathic inflammatory myopathies (CYTB323L12201). It also confirmed Phase 1/2 studies in rheumatoid arthritis and Sjogren's disease, generalized myasthenia gravis, relapsing multiple sclerosis and non-active progressive multiple sclerosis (CYTB323M12101B, CYTB323O12101, CYTB323N12101 and CYTB323R12101). The company said its oncology programme with the same asset is not affected by the halt. That programme covers chronic lymphocytic leukemia and small lymphocytic lymphoma, and diffuse large B-cell lymphoma. It also covers adult acute lymphoblastic leukemia and high-risk large B-cell lymphoma.
What is IEC-HS?
IEC-HS stands for immune effector cell-associated hemophagocytic syndrome. It is a severe systemic inflammatory side effect associated with immunotherapies such as CAR-T cell therapy. The reaction may be triggered when engineered T cells rapidly expand and activate inside the patient's body. That mechanism is why the manufacturing question in this story matters: the toxicity is tied to how hard the cells expand.
What did Bristol Myers Squibb pause?
Bristol Myers Squibb paused enrolment in autoimmune trials of zola-cel (BMS-986353), its own autologous CD19-targeted CAR-T. William Blair analysts flagged the pause in a note to clients and reported that the company later described it as due to transient and reversible inflammatory events. A BMS spokesperson called it a voluntary pause implemented out of an abundance of caution to review clinical data across the zola-cel programme. Zola-cel acts through the same CD19 mechanism as Breyanzi, an FDA-approved BMS treatment for relapsed and refractory blood cancers.
Is rapid manufacturing the cause?
Nobody has established that. Rap-cel is made on Novartis' T-Charge platform and zola-cel on BMS' NEXT T platform, both rapid manufacturing platforms. Because both assets came off rapid platforms, William Blair analysts suggested that rapid manufacturing could be driving increased cell expansion and the reported toxicities. That is a hypothesis in an analyst note. It is not a finding from either sponsor and not a regulatory conclusion, and neither pause is described as a regulator-imposed action.
Sources
- UPDATED: Novartis halts autoimmune CAR-T trials after 3 deaths, as BMS also pauses studies – Marissa Russo, Fierce Biotech, August 31, 2026, 6:25pm, with an editor's note added August 31 at 10:10 p.m. ET confirming the three serious IEC-HS cases were deaths. Every factual claim in this article traces to this report, including the trial protocol numbers, the Novartis and BMS statements, the platform descriptions and the William Blair remarks.
- William Blair client note, Monday, August 31, 2026 – quoted within the Fierce Biotech report above, and the origin of the suggestion that rapid manufacturing could be driving increased cell expansion and the reported toxicities. Not independently retrieved for this article; no separate link is offered because none appears in the source.
Join the GTC Expert Network
Independent Experts
Independent experts in cell & gene therapy: share knowledge, help build a report, or contribute quietly. Build authority and get called for paid consulting work. Join free.
Early R&D Experts
Early R&D ExpertsContribute target validation, vector engineering, or transgene design expertise. Get matched to paid consulting work through content you help create.
Join FreeCMC Experts
CMC ExpertsContribute scale-up, tech transfer, or GMP manufacturing expertise. Get matched to paid consulting work through content you help create.
Join FreeRegulatory Affairs Experts
Regulatory Affairs ExpertsContribute IND/BLA strategy or regulatory liaison expertise. Get matched to paid consulting work through content you help create.
Join FreeCommercial & Strategy Experts
Commercial & Strategy ExpertsContribute due diligence, licensing, or market access expertise. Get matched to paid consulting work through content you help create.
Join FreeEnabling Technology Experts
Enabling Technology ExpertsContribute bioprocessing hardware, analytical tooling, or supply-chain expertise. Get matched to paid consulting work through content you help create.
Join FreeAI Transformation Experts
AI Transformation ExpertsContribute agentic workflow, LLM, or AI-driven vector design expertise. Get matched to paid consulting work through content you help create.
Join FreeIndustry Representatives
Industry professionals in cell & gene therapy: de-risk your pipeline with expert input on demand, exactly when your program needs it. Join free.
Drug Developers
Drug DevelopersFounders, CSOs, VPs of R&D
Practical guides spanning vector design through commercialization, plus direct access to the expert network that wrote them.
Join FreeInvestors / VCs
Investors / VCsVC Fund Managers, Family Offices, Angels
Due diligence frameworks and strategic intelligence for evaluating CGT assets, from experts who do this diligence for a living.
Join FreeTechnology Developers
Technology DevelopersFounders, Licensing & Commercial Leads
IP protection and platform strategy guides for enabling technologies, plus the network that built them.
Join FreeCDMOs / CROs
CDMOs / CROsBD, Operations & Technical Leads
Partner selection, vendor evaluation, and operational excellence guides, sourced from the CGT organisations that use them.
Join FreeVendors / Suppliers
Vendors / SuppliersCommercial & Technical Leads
Market intelligence and partnership strategies for supply chain companies serving cell and gene therapy.
Join FreeStrategy Consultants
Strategy ConsultantsConsultants, Market Access Advisors
Spot the problems before they cost your clients — join the network that shapes what GTC covers next.
Join FreeAI Transformation Partners
AI Transformation PartnersAI/ML Consultancies, Digital Transformation Firms
AI education, implementation, and consulting for operational excellence in cell and gene therapy — for companies building or buying AI capability.
Join FreeWhere the analysis comes from. Industry teams get expert input on demand; independent experts build authority and get called for paid consulting work.
See more of our work in Google Search
Google lets you pick the sites you want to see more often in Top Stories. Add Gene Therapy Consultancy to your list, and our daily gene therapy news will show up higher for you.